---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-060654"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2021-12-17T23:59:59+00:00"
generated_at: "2026-06-28T00:16:39.665770+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Director J. Martin Carroll resigns from TherapeuticsMD board effective Dec 31, 2021

## Summary
- J. Martin Carroll notified the company of his resignation from the board on Dec 13, 2021.
- Resignation is effective December 31, 2021.
- Company states the resignation is not due to any disagreement with operations, policies, or practices.

## SEC filing metadata
- accession: 0001564590-21-060654
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2021-12-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000156459021060654/0001564590-21-060654-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000156459021060654/txmd-8k_20211213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-060654
- JSON: https://secwatch.observer/filing/0001564590-21-060654.json
- Plain text: https://secwatch.observer/filing/0001564590-21-060654.txt

## Key facts
- Executive change
  J. Martin Carroll resigned as director at TherapeuticsMD, Inc..
  - Action: resigned
  - Role: director
  source text: On December 13, 2021, Mr. J. Martin Carroll notified TherapeuticsMD, Inc., a Nevada corporation (the “Company”), of his decision to resign from the board of directors of the Company, effective December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000156459021060654/0001564590-21-060654-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.